Beda Pharmaceuticals MerTK/FLT3 Dual Target Inhibitor Siudo-Clinic Clinical For Solid Tumors
-
Last Update: 2020-07-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
MRX2843 is a new, powerful, oral bioavailable small molecule inhibitor and a new chemical structure owned by Beida, Mer Tyrosine Kinase (MerTK) and FMS-like tyrosine kinase 3 (FLT3) double inhibitorMerTK and FLT3 have expressed or changed in a variety of tumors, MRXX2843 affects tumor growth by inhibiting MerTK and FLT3 on the inherent immune cells of tumor microenvironments, thereby influencing their critical signaling pathways to affect tumor growth or by treating the tumor through immunomodulationInsight database, MRXX2843 has been in the United States for phase 1 clinical use of solid tumors for blood tumors, acute lymphoblastic leukemia, acute granulocytic leukemia has been approved clinically;Picture Source: Insight Database
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
